NGEN
NervGen Pharma Corp.
Price Chart
Latest Quote
$1.54
+0.12 (+8.45%)
Current Price
| Previous Close | $1.42 |
| Open | $1.43 |
| Day High | $1.55 |
| Day Low | $1.42 |
| Volume | 278,037 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 107.52M |
| Cash Equivalents | $61.79M |
| Net Income | $-15.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $165.58M |
| EPS (TTM) | $-0.57 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $65.89M |
| Income | $-15.83M |
| Book/sh | $0.31 |
| Cash/sh | $0.81 |
| Employees | 9 |
Financial Ratios
| Quick Ratio | 2.01 |
| Current Ratio | 2.07 |
Returns & Margins
| ROA | -38.04% |
| ROE | -96.84% |
Ownership
| Insider Ownership | 15.61% |
| Institutional Ownership | 11.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.55 |
| P/B | 4.92 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $10.00 |
Technical Indicators
| SMA20 | $1.64 |
| SMA50 | $1.91 |
| SMA200 | $2.91 |
| RSI | 33.05 |
| ATR | 0.0927 |
| Shares Float | 95.30M |
| Short Ratio | 10.82 |
| Volatility | 0.82 |
| Rel Volume | 0.59 |
Performance History
| Week | +0.00% |
| Month | -18.09% |
| Quarter | -3.14% |
| 6 Months | -60.31% |
| YTD | -73.81% |
| Year | -44.00% |
| 3 Years | +19.20% |
| 5 Years | -24.14% |
| 10 Years | +18.37% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.54 | 278,037 |
| 2026-10-26 | $1.42 | 259,200 |
| 2026-10-23 | $1.43 | 944,000 |
| 2026-10-22 | $1.42 | 628,400 |
| 2026-10-21 | $1.50 | 297,500 |
| 2026-10-20 | $1.54 | 228,400 |
| 2026-10-19 | $1.54 | 423,100 |
| 2026-10-16 | $1.59 | 388,300 |
| 2026-10-15 | $1.62 | 475,200 |
| 2026-10-14 | $1.57 | 1,298,900 |
| 2026-10-13 | $1.63 | 506,400 |
| 2026-10-12 | $1.73 | 220,500 |
| 2026-10-09 | $1.73 | 293,200 |
| 2026-10-08 | $1.75 | 288,900 |
| 2026-10-07 | $1.74 | 231,500 |
| 2026-10-06 | $1.75 | 297,800 |
| 2026-10-05 | $1.81 | 441,000 |
| 2026-10-02 | $1.78 | 403,600 |
| 2026-10-01 | $1.76 | 1,049,400 |
| 2026-09-30 | $1.91 | 548,400 |
| 2026-09-29 | $1.92 | 556,800 |
| 2026-09-28 | $1.88 | 525,400 |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
đ° Latest News
No news articles available at the moment. Check back later for updates on NGEN.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $17,931,555 | $18,000,836 | $12,710,269 | $16,462,797 |
| Other Income Expense | $-13,850,514 | $81,140 | $-3,686,148 | $1,870,395 |
| Net Non Operating Interest Income Expense | $238,390 | $581,018 | $393,300 | $-223,939 |
| Operating Expense | $17,931,555 | $18,000,836 | $12,710,269 | $16,462,797 |
| General And Administrative Expense | $7,987,964 | $6,676,004 | $6,886,712 | $4,531,937 |
| Interest Expense | - | - | $0 | $367,936 |
| Interest Expense Non Operating | - | - | $0 | $367,936 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Net Interest Income | $238,390 | $581,018 | $393,300 | $-223,939 |
| Interest Income | $238,390 | $581,018 | $393,300 | $143,997 |
| Normalized Income | $-17,693,165 | $-17,419,818 | $-12,316,969 | $-16,686,736 |
| Net Income From Continuing And Discontinued Operation | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Net Income Common Stockholders | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Net Income | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Net Income Including Noncontrolling Interests | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Net Income Continuous Operations | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Pretax Income | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Interest Income Non Operating | $238,390 | $581,018 | $393,300 | $143,997 |
| Operating Income | $-17,931,555 | $-18,000,836 | $-12,710,269 | $-16,462,797 |
| Depreciation Amortization Depletion Income Statement | $0 | $20,022 | $70,479 | $52,456 |
| Depreciation And Amortization In Income Statement | $0 | $20,022 | $70,479 | $52,456 |
| Depreciation Income Statement | $0 | $20,022 | $70,479 | $52,456 |
| Per Share | ||||
| Diluted EPS | $-0.44 | $-0.26 | $-0.27 | $-0.28 |
| Basic EPS | $-0.44 | $-0.26 | $-0.27 | $-0.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,041,147 | $-18,022,060 | $-8,920,445 | $-16,236,494 |
| Total Unusual Items | $-13,850,514 | $81,140 | $-3,686,148 | $1,870,395 |
| Total Unusual Items Excluding Goodwill | $-13,850,514 | $81,140 | $-3,686,148 | $1,870,395 |
| Reconciled Depreciation | $39,893 | $59,915 | $103,676 | $82,306 |
| EBITDA (Bullshit earnings) | $-17,891,662 | $-17,940,921 | $-12,606,594 | $-14,366,099 |
| EBIT | $-17,931,555 | $-18,000,836 | $-12,710,269 | $-14,448,405 |
| Diluted Average Shares | $51,716,281 | $48,134,718 | $42,392,123 | $37,643,828 |
| Basic Average Shares | $51,716,281 | $48,134,718 | $42,392,123 | $37,643,828 |
| Diluted NI Availto Com Stockholders | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Gain On Sale Of Security | $-13,850,514 | $81,140 | $-3,686,148 | $1,870,395 |
| Research And Development | $9,943,591 | $11,304,810 | $5,753,078 | $11,878,404 |
| Selling General And Administration | $7,987,964 | $6,676,004 | $6,886,712 | $4,531,937 |
| Other Gand A | $3,149,567 | $1,893,792 | $2,050,591 | $2,189,053 |
| Salaries And Wages | $4,838,397 | $4,782,212 | $4,836,122 | $2,342,884 |
Fetched: 2026-10-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,193,437 | $1,509,820 | $-1,808,837 | $9,316,162 |
| Total Assets | $16,594,791 | $13,932,564 | $9,463,697 | $17,070,675 |
| Total Non Current Assets | $292,550 | $338,427 | $515,179 | $519,575 |
| Goodwill And Other Intangible Assets | $292,550 | $332,443 | $372,336 | $308,451 |
| Other Intangible Assets | $292,550 | $332,443 | $372,336 | $308,451 |
| Current Assets | $16,302,241 | $13,594,137 | $8,948,517 | $16,551,100 |
| Other Current Assets | $458,776 | $75,549 | $11,676 | - |
| Current Deferred Assets | $0 | $293,332 | $0 | - |
| Receivables | $57,790 | $296,938 | $178,898 | $19,324 |
| Other Receivables | $18,100 | $193,510 | $178,662 | - |
| Taxes Receivable | $39,689 | $103,428 | $236 | - |
| Cash Cash Equivalents And Short Term Investments | $15,785,676 | $12,415,701 | $8,336,523 | $16,052,794 |
| Cash And Cash Equivalents | $15,779,692 | $12,346,179 | $8,336,523 | $16,052,794 |
| Prepaid Assets | - | $512,617 | $421,421 | $478,981 |
| Accounts Receivable | - | - | $178,898 | $19,324 |
| Cash Financial | - | - | - | $16,052,794 |
| Debt | ||||
| Total Debt | $5,984 | $75,506 | $140,990 | $202,669 |
| Long Term Debt And Capital Lease Obligation | $0 | $5,984 | $75,506 | $140,990 |
| Current Debt And Capital Lease Obligation | $5,984 | $69,522 | $65,484 | $61,679 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $14,108,804 | $12,090,301 | $10,900,198 | $7,446,062 |
| Total Non Current Liabilities Net Minority Interest | $0 | $5,984 | $75,506 | $140,990 |
| Current Liabilities | $14,108,804 | $12,084,317 | $10,824,692 | $7,305,072 |
| Other Current Liabilities | $10,772,766 | $8,481,769 | $8,427,456 | $4,813,553 |
| Payables And Accrued Expenses | $2,355,569 | $2,701,810 | $1,823,825 | $2,429,840 |
| Payables | $19,637 | $23,909 | $2,374,649 | $1,791,966 |
| Other Payable | $19,637 | $23,909 | - | - |
| Accounts Payable | - | - | $2,374,649 | $1,431,361 |
| Equity | ||||
| Common Stock Equity | $2,485,987 | $1,842,263 | $-1,436,501 | $9,624,613 |
| Total Equity Gross Minority Interest | $2,485,987 | $1,842,263 | $-1,436,501 | $9,624,613 |
| Stockholders Equity | $2,485,987 | $1,842,263 | $-1,436,501 | $9,624,613 |
| Gains Losses Not Affecting Retained Earnings | $33,777,430 | $17,180,295 | $12,306,785 | $8,451,448 |
| Retained Earnings | $-104,935,270 | $-73,391,591 | $-55,879,069 | $-39,875,952 |
| Other | ||||
| Ordinary Shares Number | $56,948,868 | $50,287,892 | $42,618,313 | $42,026,781 |
| Share Issued | $56,948,868 | $50,287,892 | $42,618,313 | $42,026,781 |
| Tangible Book Value | $2,193,437 | $1,509,820 | $-1,808,837 | $9,316,162 |
| Invested Capital | $2,485,987 | $1,842,263 | $-1,436,501 | $9,624,613 |
| Working Capital | $2,193,437 | $1,509,820 | $-1,876,174 | $9,246,028 |
| Capital Lease Obligations | $5,984 | $75,506 | $140,990 | $202,669 |
| Total Capitalization | $2,485,987 | $1,842,263 | $-1,436,501 | $9,624,613 |
| Capital Stock | $73,643,826 | $58,053,559 | $42,135,783 | $41,049,116 |
| Common Stock | $73,643,826 | $58,053,559 | $42,135,783 | $41,049,116 |
| Long Term Capital Lease Obligation | $0 | $5,984 | $75,506 | $140,990 |
| Current Capital Lease Obligation | $5,984 | $69,522 | $65,484 | $61,679 |
| Pensionand Other Post Retirement Benefit Plans Current | $974,485 | $831,217 | $507,927 | - |
| Current Accrued Expenses | $2,335,932 | $2,677,901 | $1,823,825 | $637,873 |
| Investments And Advances | $0 | $5,984 | $0 | - |
| Other Investments | $0 | $5,984 | $0 | - |
| Net PPE | $0 | $0 | $142,843 | $211,124 |
| Gross PPE | $0 | $0 | $142,843 | $211,124 |
| Other Short Term Investments | $5,984 | $69,522 | $0 | - |
| Dueto Related Parties Current | - | - | $313,586 | $360,605 |
| Other Properties | - | - | $142,843 | $211,124 |
Fetched: 2026-10-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,941,850 | $-12,041,265 | $-8,177,403 | $-12,730,688 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,941,850 | $-12,041,265 | $-8,076,300 | $-12,715,598 |
| Cash Flow From Continuing Operating Activities | $-13,941,850 | $-12,041,265 | $-8,076,300 | $-12,715,598 |
| Operating Gains Losses | $13,234,515 | $312,558 | $3,662,556 | $-1,855,988 |
| Investing Activities | ||||
| Investing Cash Flow | $72,162 | $42,095 | $-99,280 | $-15,090 |
| Cash Flow From Continuing Investing Activities | $72,162 | $42,095 | $-99,280 | $-15,090 |
| Capital Expenditure | - | - | $-101,103 | $-15,090 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,072,457 | $16,453,327 | $0 | $14,130,323 |
| Financing Cash Flow | $16,991,110 | $16,226,905 | $547,890 | $16,188,526 |
| Cash Flow From Continuing Financing Activities | $16,991,110 | $16,226,905 | $547,890 | $16,188,526 |
| Net Other Financing Charges | $-638,336 | $-1,165,687 | - | $-92,264 |
| Net Common Stock Issuance | $12,072,457 | $16,453,327 | $0 | $14,130,323 |
| Common Stock Issuance | $12,072,457 | $16,453,327 | $0 | $14,130,323 |
| Other | ||||
| Repayment Of Debt | $-72,162 | $-72,162 | $-72,162 | $-54,122 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $15,779,692 | $12,346,179 | $8,336,523 | $16,052,794 |
| Beginning Cash Position | $12,346,179 | $8,336,523 | $16,052,794 | $12,104,058 |
| Effect Of Exchange Rate Changes | $312,091 | $-218,078 | $-88,582 | $490,898 |
| Changes In Cash | $3,121,422 | $4,227,734 | $-7,627,690 | $3,457,838 |
| Proceeds From Stock Option Exercised | $5,629,151 | $1,011,426 | $620,052 | $2,204,590 |
| Net Issuance Payments Of Debt | $-72,162 | $-72,162 | $-72,162 | $-54,122 |
| Net Long Term Debt Issuance | $-72,162 | $-72,162 | $-72,162 | $-54,122 |
| Long Term Debt Payments | $-72,162 | $-72,162 | $-72,162 | $-54,122 |
| Net Intangibles Purchase And Sale | $72,162 | $42,095 | $-97,082 | $0 |
| Sale Of Intangibles | $72,162 | $42,095 | $0 | - |
| Change In Working Capital | $470,081 | $599,564 | $-171,848 | $1,512,189 |
| Change In Payables And Accrued Expense | $-191,790 | $877,573 | $-53,259 | $1,659,017 |
| Change In Prepaid Assets | $422,722 | $-159,970 | $40,985 | $-173,266 |
| Change In Receivables | $239,149 | $-118,040 | $-159,574 | $26,437 |
| Changes In Account Receivables | $239,149 | $-118,040 | $-159,574 | $26,437 |
| Stock Based Compensation | $3,857,340 | $4,318,376 | $4,321,951 | $1,984,075 |
| Depreciation Amortization Depletion | $39,893 | $59,915 | $103,676 | $82,306 |
| Depreciation And Amortization | $39,893 | $59,915 | $103,676 | $82,306 |
| Amortization Cash Flow | $39,893 | $39,893 | $33,197 | $29,850 |
| Amortization Of Intangibles | $39,893 | $39,893 | $33,197 | $29,850 |
| Depreciation | $0 | $20,022 | $70,479 | $52,456 |
| Gain Loss On Investment Securities | $13,557,789 | $97,210 | $3,571,005 | $-1,365,090 |
| Net Foreign Currency Exchange Gain Loss | $-323,274 | $210,450 | $91,550 | $-490,898 |
| Gain Loss On Sale Of PPE | $0 | $4,898 | $0 | - |
| Net Income From Continuing Operations | $-31,543,679 | $-17,338,678 | $-16,003,117 | $-14,816,341 |
| Purchase Of Intangibles | - | $0 | $-97,082 | $0 |
| Net PPE Purchase And Sale | - | $0 | $-2,198 | $-15,090 |
| Sale Of PPE | - | $0 | $1,823 | $0 |
| Purchase Of PPE | - | $0 | $-4,020 | $-15,090 |
| Other Non Cash Items | - | $7,000 | $10,483 | $378,161 |
| Change In Payable | - | - | - | $1,659,017 |
| Change In Account Payable | - | - | - | $1,659,017 |
Fetched: 2026-10-23